February 2025's Estimated Undervalued Stock Selections For Savvy Investors

In This Article:

As global markets navigate a landscape marked by volatile corporate earnings and geopolitical tensions, investors are keenly observing the impact of AI competition and central bank policies on stock performance. Amidst this uncertainty, identifying undervalued stocks can be a strategic move, as these equities may offer potential value relative to their current market price when considering factors such as solid fundamentals or promising growth prospects.

Top 10 Undervalued Stocks Based On Cash Flows

Name

Current Price

Fair Value (Est)

Discount (Est)

Reach Subsea (OB:REACH)

NOK8.06

NOK16.12

50%

TF Bank (OM:TFBANK)

SEK376.00

SEK750.28

49.9%

Telefonaktiebolaget LM Ericsson (OM:ERIC B)

SEK82.94

SEK165.72

50%

Tongqinglou Catering (SHSE:605108)

CN¥20.86

CN¥41.56

49.8%

Decisive Dividend (TSXV:DE)

CA$5.97

CA$11.89

49.8%

Northwest Bancshares (NasdaqGS:NWBI)

US$13.23

US$26.31

49.7%

Groupe Dynamite (TSX:GRGD)

CA$16.11

CA$32.07

49.8%

Sociedad Química y Minera de Chile (NYSE:SQM)

US$37.70

US$75.20

49.9%

Verra Mobility (NasdaqCM:VRRM)

US$26.04

US$51.68

49.6%

Kyndryl Holdings (NYSE:KD)

US$43.45

US$86.66

49.9%

Click here to see the full list of 928 stocks from our Undervalued Stocks Based On Cash Flows screener.

Let's dive into some prime choices out of the screener.

ALTEOGEN

Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩20.04 trillion.

Operations: The company's revenue segment is focused on biotechnology, generating approximately ₩74.38 billion.

Estimated Discount To Fair Value: 48.5%

Alteogen Inc. is trading significantly below its estimated fair value, with a share price of ₩392,000 compared to a calculated fair value of ₩761,427.11. The company's revenue is projected to grow at 84.2% annually, outpacing the market average and contributing to expectations of profitability within three years. Recent strategic moves include a private placement raising KRW 154 billion and an exclusive licensing agreement with Daiichi Sankyo for ALT-B4 technology, potentially enhancing future cash flows through milestone payments and royalties.

KOSDAQ:A196170 Discounted Cash Flow as at Feb 2025
KOSDAQ:A196170 Discounted Cash Flow as at Feb 2025

Hua Hong Semiconductor

Overview: Hua Hong Semiconductor Limited is an investment holding company that manufactures and sells semiconductor products, with a market capitalization of approximately HK$53.94 billion.

Operations: Hua Hong Semiconductor generates revenue primarily from the manufacturing and sale of semiconductor products.